Customize
Quick Links

Accreditation/
Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669 for 2.0 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from AstraZeneca.

About
Accreditation
Privacy Policy
Terms & Conditions
Executive Board
Journal
Faculty Portal
Contact
Facebook
Twitter
LinkedIn
Google +
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2017
Physicians’ Education Resource ®, LLC.
All rights reserved.

ASCO: PARP Inhibition in Breast Cancer: Practical Methods to Interpret and Apply the Evidence for Your Patients

ASCO: PARP Inhibition in Breast Cancer: Practical Methods to Interpret and Apply the Evidence for Your Patients


Date: Friday, June 1, 2018

Time: 7:00 PM – 9:00 PM
Dinner and registration: 6:30 PM – 7:00 PM

Location:
Chicago Hilton Hotel
Continental Ballroom (Lobby Level)
720 S. Michigan Avenue
Chicago, IL 60605

Overview

A great deal of progress has been made in the understanding of the mechanistic underpinnings for the use of PARP inhibitor therapy in the treatment of patients with breast cancer. As the level of evidence continues to accumulate, it is important for clinicians to be able to apply clinical data to the development of treatment paradigms that maximize outcomes for their patients. This includes efficacy considerations, as well as development of strategies to identify and mitigate predictable treatment-related adverse events in a timely fashion. As PARP inhibition may soon enter clinical practice for patients with breast cancer, a robust discussion of applicable case scenarios can help clinicians bridge the gap between clinical trial investigation and clinical application.

In order to help busy clinicians optimize the management of their patients, this interactive educational activity will highlight the latest clinical evidence pertaining to the use of PARP inhibitors in the management of patients with breast cancer. The format will include a combination of didactic presentations and brief panel discussions framed by clinically applicable case presentations. There will also be multiple opportunities for audience members to present questions to the panel of clinical experts.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from AstraZeneca.

Target Audience

This educational activity is directed toward medical oncologists who treat patients with breast cancer. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of breast cancer are also invited to participate.

Learning Objectives

Upon completion of this activity, participants should be better prepared to:

  • Outline the mechanistic rationale that underlies the application of PARP inhibition approaches for the management of breast cancer
  • Apply key evidence from PARP inhibition trials in breast cancer, and report recent findings from investigations evaluating potential new roles for these approaches
  • Summarize strategies to mitigate predictable toxicities that have been reported with the use of PARP inhibition strategies
  • Identify strategies that are being explored to maximize the efficacy of PARP inhibition in the treatment of patients with breast cancer

Program Chair
Mark E. Robson, MD
Attending Physician
Clinical Genetics and Breast Medicine Services
Clinic Director, Clinical Genetics Service
Memorial Sloan Kettering Cancer Center
New York, NY







Become a Member

Forgot Password?
Filter By